Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Merck
Express Scripts
Colorcon
Moodys
Medtronic

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Biapenem

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Biapenem?

Biapenem is an investigational drug.

There have been 4 clinical trials for Biapenem. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2017.

The most common disease conditions in clinical trials are Bacterial Infections, Neoplasm Metastasis, and [disabled in preview]. The leading clinical trial sponsors are Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), Haining Health-Coming Biotech Co., Ltd., and [disabled in preview].

There are seven hundred and forty-four US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for Biapenem
TitleSponsorPhase
Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid TumorHaining Health-Coming Biotech Co., Ltd.Phase 2
Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in CombinationRempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Phase 1
Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult SubjectsRempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Phase 1

See all Biapenem clinical trials

Clinical Trial Summary for Biapenem

Top disease conditions for Biapenem
Top clinical trial sponsors for Biapenem

See all Biapenem clinical trials

US Patents for Biapenem

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Biapenem   Start Trial Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
Biapenem   Start Trial Cyclic boronic acid ester derivatives and methods of making the same Rempex Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Biapenem   Start Trial Methods of treating inflammation associated airway diseases and viral infections WASHINGTON STATE UNIVERSITY (Pullman, WA) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Merck
Harvard Business School
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.